BALLERUP, Denmark–(BUSINESS WIRE)–As part of LEO Pharma’s transformation to become a global leader in medical dermatology, the company today announced a refocused business structure to support building a simpler, nimble and competitive business.
Commercial responsibilities within the Global Leadership Team (GLT) are consolidated, reducing the number of commercial members. It means that:
The Europe+ region and the International region are merged with Global Therapeutic & Value Strategy in a newly created role within the global leadership team: Global Product Strategy & International Operations. The new lead role will be held by Executive Vice President Becki Morison, who joined LEO Pharma in October 2020 as Executive Vice President Global Therapeutics & Value Strategy.
The US region is merged with the Canadian subsidiary to form the North America region. The new region will be led by Executive Vice President Brian Hilberdink, who joined LEO Pharma in February 2022 as President of LEO Pharma Inc. in the United States.
The creation of a leaner and simpler global management team with consolidated commercial representation is a natural next step from the key actions announced in January 2022, focused on increasing the competitiveness of LEO Pharma. The refocused business setup will increase organizational efficiency and alignment of all business functions globally and ensure full focus on launching tralokinumab in all markets for future growth.
Both Becki and Brian bring strong commercial leadership experience in global and US contexts, which ensures close collaboration in all markets.
– A central element of our strategy is to adapt our organization to become more efficient and more competitive. As we simplify and streamline the organization, this should also be reflected in a leaner and more agile composition of our Global leadership team. We are now taking the step to fully commit to simplifying our organization. With Becki and Brian leading the refocused business structure, we are well positioned for global growth and to help more patients, said Christophe Bourdon, CEO of LEO Pharma, and clarified:
– Becki has extensive experience at global, regional and affiliate levels and has successfully increased the competitiveness of brands and businesses across multiple areas of chronic therapy and global pharmaceutical companies. During her career, Becki has led significant transformations in key geographies, including Northern Europe, Australia and the United States, which have delivered significant EBITDA improvement and driven demand across the market.
– Brian Hilberdink has over 25 years of global experience developing and executing product strategies and launches in the pharmaceutical industry, most recently in senior sales and marketing leadership roles for Novo Nordisk in the US , in Canada and around the world – an experience that makes him an excellent fit for this expanded role.
As part of these changes, Monica Shaw, former Executive Vice President of Europe+ Region, will leave LEO Pharma effective June 30, 2022. Guillaume Clement, former Executive Vice President of International Region and Thrombosis, will continue as a member of the global management team in charge of LEO Pharma’s thrombosis business. Unity.
– I I would like to thank Monica for her contribution and leadership during her tenure as a valued leader within LEO Pharma’s global leadership team. She has been instrumental in bringing the business to where it is today: supporting the growth of our existing portfolio, preparing our markets for the launch of tralokinumab, and supporting the organization through the early stages of our transformation.said CEO Christophe Bourdon.
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority-owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advancing the science of dermatology, and today the company offers a wide range of therapies for all severities of sickness. LEO Pharma is headquartered in Denmark and has a global team of 5,800 people, serving millions of patients around the world. In 2021, the company achieved a net turnover of DKK 9,957 million.